Sutro Biopharma
STRO
Sutro Biopharma (STRO) news
Recent news
Sutro Biopharma Inc: Stifel initiates coverage with buy rating; price target $48
Stifel has initiated coverage of Sutro Biopharma Inc (NASDAQ: STRO), assigning the biotechnology company a "Buy" rating and a price target of $48 per share [1]. The firm's analysts highlighted Sutro's innovative platform for developing precision oncology therapies and its robust pipeline as key…
AInvest Wire · Aug 7, 2026Sutro Biopharma Inc: Truist Securities assumes coverage with buy rating; target price $50
AInvest Wire · Jun 11, 2026ImportantSutro Biopharma jumps 16% in premarket trading.
AInvest Wire · Nov 30, 2023Wedbush reiterates outperform on Sutro Biopharma, maintains $12 price target.
AInvest Wire · Oct 23, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.